Peak expiratory flow rate as a surrogate for forced expiratory volume in 1 second in COPD severity classification in Thailand
Received 20 March 2015
Accepted for publication 13 May 2015
Published 25 June 2015 Volume 2015:10(1) Pages 1213—1218
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Richard Russell
Chaicharn Pothirat, Warawut Chaiwong, Nittaya Phetsuk, Chalerm Liwsrisakun, Chaiwat Bumroongkit, Athavudh Deesomchok, Theerakorn Theerakittikul, Atikun Limsukon
Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Background: There are limited studies directly comparing correlation and agreement between peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV1) for severity classification of COPD. However, clarifying the role of PEFR as a surrogate of COPD severity classification instead of FEV1 is essential in situations and areas where spirometry is not routinely available.
Purpose: To evaluate the agreement between FEV1 and PEFR using Global initiative for chronic Obstructive Lung Disease (GOLD) severity classification criteria.
Materials and methods: This cross-sectional study included stable COPD patients. Both absolute values and % predicted FEV1 and % predicted PEFR were obtained from the same patients at a single visit. The severity of COPD was classified according to GOLD criteria. Pearson’s correlation coefficient was used to examine the relationship between FEV1 and PEFR. The agreement of % predicted FEV1 and % predicted PEFR in assigning severity categories was calculated using Kappa statistic, and identification of the limits of agreement was by Bland–Altman analysis. Statistical significance was set at P-value <0.05.
Results: Three hundred stable COPD patients were enrolled; 195 (65.0%) male, mean age 70.4±9.4 years, and mean % predicted FEV1 51.4±20.1. Both correlations between the % predicted FEV1 and PEFR as well as the absolute values were strongly significant (r=0.76, P<0.001 and r=0.87, P<0.001, respectively). However, severity categories of airflow limitation based on % predicted FEV1 or PEFR intervals were concordant in only 179 patients (59.7%). The Kappa statistic for agreement was 0.41 (95% confidence interval, 0.34–0.48), suggesting unsatisfied agreement. The calculated limits of agreement were wide (+27.1% to -28.9%).
Conclusion: Although the correlation between FEV1 and PEFR measurements were strongly significant, the agreement between the two tests was unsatisfied and may influence inappropriate clinical decision making in diagnosis, severity classification, and management of COPD.
Keywords: chronic obstructive pulmonary disease, spirometry, agreement
Both percentages of predicted forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR) are widely used to estimate the degree of pulmonary impairment in patients with COPD.1–3 In general, FEV1 measurements by spirometry are preferred as it is much more reproducible.4 However, spirometry is not widely available, and the technical pitfalls of performing spirometry frequently limit usage, especially at a primary care level.5 Using PEFR measurement is more economical and much more widely available, therefore it is proposed as an alternative to spirometry.1–3
Definition and severity assessments of COPD severity are now based on post-bronchodilator ratio FEV1 and forced vital capacity (FEV1/FVC) and % predicted FEV1 measurements, respectively.6 Recent reports suggest that peak flow measurements may be an inexpensive way of screening7 and initial identification of severe cases of COPD for subsequent confirmatory spirometry.8–10 In general, the correlation coefficients between % predicted PEFR and % predicted FEV1 was moderate to good ranging from 0.5 to >0.9;11–13 however, the degree of agreement between the two estimates were unsatisfactory.3,14 The factors that precluded generalization of the results from these studies in COPD included: small numbers of patients,3,11,12 recording multiple paired estimates on each subject and analyzing each pair as a separate variable,3 and conducting in heterogeneous subjects (persistent cough subjects,13 asthma12 or mixed subjects with asthma and COPD).3,14 Since clinical decisions are often based on results of these two measurements, we intended to clarify the role of PEFR as a surrogate for FEV1 in COPD severity classification.
Materials and methods
Outpatients aged over 40 years diagnosed with COPD by Global initiative for chronic Obstructive Lung Disease (GOLD) criteria6 were treated at the chest clinic, Chiang Mai University Hospital, Chiang Mai, Thailand from 1 April 2012 to 30 September 2012 and were screened for this study. Inclusion criteria were: smokers or ex-smokers with a smoking history of ≥10 pack-years, aged ≥40 years, and no exacerbations >6 weeks prior to enrollment. Patients were excluded if they had a history or family history of asthma, onset of breathlessness at age <40 years, and unable to perform spirometry or peak expiratory flow maneuver. Accurate measurements of both spirometry and PEFR in the same subject were administered by a qualified technician in the study team. Both FEV1 and PEFR were obtained from the same patients at a single visit using spirometer (Vmax series 22, Sensormedics, Bilthoven, Holland). All subjects were measured for post-bronchodilator FVC, FEV1, ratio of FEV1/FVC (FEV1%) using ATS/ERS standard guidelines15 and PEFR by a Mini-Wright peak flow meter (Clement Clarke International Ltd., Essex, UK). Each patient performed the test in a standing position while holding the peak flow meter horizontally without interfering with the movement of the marker (arrow) or covering the slot. Patients were instructed to take a deep breath then exhale by forceful expiration as fast as possible while maintaining an air tight seal between lip and mouth piece of the instrument with standard techniques developed by the American Thoracic Society.16 Technicians recorded readings only if the instrument was held in the proper horizontal position. Both % predicted FEV1 and % predicted PEFR were calculated using Thai equations,17 and categories of airflow limitation severity were classified according to GOLD criteria.6 The study protocol was approved by the Ethics Committee of the Faculty of Medicine, Chiang Mai University.
Results for numerical values were expressed as mean ± standard deviation, and those for categorical data were expressed as absolute frequencies and percentages. Comparisons of the measurements between FEV1 and PEFR using paired Student’s t-test. Pearson’s correlation was used to examine the relationship between FEV1 and PEFR. COPD severity using FEV1 and PEFR were compared using Fisher’s exact tests. Measurements of lung function were used to classify the severity of airflow limitation (according to GOLD criteria)6 with 0-<30%, 30-<50%, 50-<80%, and ≥80% for both predicted FEV1 and PEFR values representing very severe, severe, moderate, and mild severity, respectively. The agreement between severity category assignment using % predicted FEV1 and % predicted PEFR was calculated using Cohen’s Kappa statistic calculations.18 A Kappa value of greater than 0.60 was considered sufficient to ensure agreement.19 Bland–Altman analysis was used to identify the limits of agreement between the two estimates.20 Statistical significance was set at P-value <0.05. All analyses were carried out using SPSS statistical package, version 16 for Windows; SPSS, Inc; Chicago, IL, USA.
The demographic characteristics of the 300 enrolled COPD patients are shown in Table 1. The subjects were elderly (mean age 70.4±9.4 years), predominantly male (65%), and the largest proportion was classified with moderate to severe stages of disease (GOLD II 38% and III 38.7%).
Correlations between the % predicted and absolute values for FEV1 and PEFR were strongly significant (r=0.76 and 0.87, respectively). However, the scatter was wide in patients with mild airflow limitation (Figure 1).
For the entire study population, the differences between % predicted FEV1 and PEFR followed a normal distribution with approximately 40% of them having a discrepancy of ≥±10% (Figure 2), and % predicted PEFR overestimated % predicted FEV1 by a mean of only 0.9% (95% confidence interval; -2.6, 0.7) (Table 2). However, limits of agreement were wide (+27.1% to −28.9%) (Figure 3). Mean % predicted FEV1 and PEFR in each severity category of airflow limitation were assessed (Table 2). Assignment to mild and moderate groups were insignificant (P=0.068 and P=0.855, respectively). However, % predicted PEFR significantly overestimated % predicted FEV1 in severe and very severe groups (P=0.007 and P=0.006, respectively).
Figure 2 Histogram showing the near-normal distribution of differences between % predicted FEV1 and PEFR in COPD patients.
Severity categories of airflow limitation based on % predicted intervals are presented in Table 3. PEFR and FEV1 severity categories were concordant in only 59.7% of the study patients. In the mild group, PEFR underestimated the severity of airflow limitation in 45% of patients whereas it overestimated the severity of airflow limitation in 36.6% of the very severe group patients. In groups with moderate and severe airflow limitation, the percentages of over- and under-estimation by PEFR for each group are also demonstrated in the table. The Kappa statistic for agreement in this table was 0.41 (95% confidence interval, 0.34–0.48), suggesting only moderate agreement between the two measurements.
This study reveals a marked variability in agreement between the measurements of % predicted FEV1 and % predicted PEFR values in COPD patients. The results provide strong evidence that the two estimates are not equivalent in the assessment of severity of airflow limitation in COPD patients. The severity classification of airflow limitation between the two estimates was concordant in only 59.7% of patients evaluated, while % predicted FEV1 and % predicted PEFR values were apart more than 10% in 40% of patients. The strong correlation between the two estimates in this study was also observed in prior studies in limited subjects with asthma and COPD,3 subjects with asthma,12 or subjects with persistent cough.13 Such a strong correlation meant that the two methods of measurements of airflow limitation in COPD patients were highly related. However, the high correlation of the two measurements is irrelevant to the question of agreement.20 In our study, the Kappa statistic for agreement suggested only moderate agreement between the two measurements which was considered insufficient to ensure agreement.19
PEFR is measured on the first effort dependent portion of the forced expiratory maneuver and predominantly reflects large airway function. FEV1 is determined both by the effort dependent and independent portions of this maneuver and reflects both large and peripheral airway function.21 Thus, different changes in FEV1 and PEFR may be observed, depending on the amount and predominant site of airway narrowing. In COPD patients, after the initial rapid rise in expiratory flow, intrathoracic pressure is increased. This increased intrathoracic pressure causes segmental and other large airways’ collapse and obstructed passage of air through those airways which results in rapid reduction in flow after a relatively normal peak has been attained, leading to significantly lower values for FEV1 compared to PEFR. These issues could lead to a significant discordance if % predicted FEV1 is replaced by % predicted PEFR for the purpose of severity classification. The mean difference between % predicted FEV1 and % predicted PEFR in this study was only 0.9% but a discrepancy of ≥10% between % predicted FEV1 and % predicted PEFR occurred in 40% of the patients. However, some previous studies showed a much wider mean difference, with % predicted FEV1 being lower than % predicted PEFR by 9.1%–17.2% because they included patients with asthma and limited numbers of evaluated patients.3,12 The mean differences between % predicted PEFR and % predicted FEV1 in this study significantly increased from 0.3% in moderate to 4.3% in very severe airflow limitation. Therefore, % predicted PEFR tended to underestimate severity of airflow limitation as the severity of COPD increased. In addition, the limits of agreement were also wide and pointed toward an absence of parity between % predicted FEV1 and % predicted PEFR.
Our study found that in patients with severe airflow limitation (severe and very severe categories) % predicted PEFR underestimated % predicted FEV1, whereas the exact opposite happened in patients with less severe airflow limitation (mild to moderate categories). It is clear from these results that if GOLD guidelines are followed and % predicted PEFR is used as a surrogate for that of FEV1, then severity of obstruction would be wrongly categorized in a large proportion of patients and could result in inappropriate diagnosis, severity classification, and management. Because of strong correlations, % predicted PEFR should be used as a surrogate for % predicted FEV1. However, the limits of agreement were wide and resulted in a significant discordance in the severity categories of airflow limitation according to GOLD classification. These values render substitution of % predicted PEFR for % predicted FEV1 “ruling out” or “ruling in” severe airflow limitation.
PEFR may not be able to accurately identify GOLD stage, but previous studies indicated some usefulness of peak flow rate measurements for daily monitoring in patients with COPD,22 COPD screening,7 and initial identification of severe cases of COPD for subsequent confirmatory spirometry.8–10 Another study states that peak expiratory flow was the most important predictive value for determining the risk of death in patients who required hospitalization for acute exacerbation of COPD.23 A recent prospective study from the People’s Republic of China shows that a lower value of height-adjusted peak flow measurement was associated with increased mortality from respiratory and other causes, including lung cancer and cardiovascular disease.24 In addition, we did not look at changes in PEFR over time, therefore we cannot rule out that PEFR may be useful in monitoring disease progression. The strengths of our study are: first, only COPD patients were studied and to our knowledge we enrolled the largest number of COPD patients for studying the agreement between the two estimates. Second, the severity categories of airflow limitation according to GOLD criteria were applied for comparison of the two measurements. Third, the measurements of FEV1 and PEFR were highly accurate because the patients were measured within a single session to avoid diurnal and day-to-day variability. Taken together, the results can be interpreted with great confidence. The major limitation of our study is that it is strictly applicable to evaluating only COPD patients treated at the chest clinic and may not be generalized to other sets of COPD patients at other clinics.
Although the correlation between FEV1 and PEFR measurements was strongly significant, the agreement between the two tests was unacceptable and may influence inappropriate clinical decision making in diagnosis, severity classification, and management of COPD.
The authors wish to thank the subjects who kindly took part in this study and to acknowledge the staff members of the Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, for their contribution to this study.
C Pothirat developed the study design and carried out acquisition and interpretation of data, statistical analysis, manuscript preparation, and critical revision of intellectual content. The remaining authors contributed to acquisition and interpretation of data, revised the article for important intellectual content, and gave final approval of the version to be published.
The authors report no conflicts of interest in this work.
Hansen EF, Vestbo J, Phanareth K, Kok-Jensen A, Dirksen A. Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(3 Pt 1): 690–693.
Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ. 2003; 327(7416):653–654.
Llewellin P, Sawyer G, Lewis S, et al. The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction. Respirology. 2002;7(4):333–337.
Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968.
Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops. Chest. 1999;116(2):416–423.
Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6): 532-555.
Maranetra N, Chuaychoo B, Naruman C, et al. The cost-effectiveness of mini peak expiratory flow as a screening test for chronic obstructive pulmonary disease among the Bangkok elderly. J Med Assoc Thai. 2003;86(12):1133-1139.
Mahboub B, Alzaabi A, Soriano JB, et al. Case-finding of chronic obstructive pulmonary disease with questionnaire, peak flow measurements and spirometry: a cross-sectional study. BMC Res Notes. 2014;7:241.
Jithoo A, Enright PL, Burney P, et al. Case-finding options for COPD: results from the Burden of Obstructive Lung Disease study. Eur Respir J. 2013;41(3):548-555.
Perez-Padilla R, Vollmer WM, Vzquez-Garcia JC, et al. Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease? Int J Tuberc Lung Dis. 2009;13(3):387-393.
Kelly CA, Gibson GJ. Relation between FEV1 and peak expiratory flow in patients with chronic airflow obstruction. Thorax. 1988; 43(4):335–336.
Teeter JG, Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest. 1998;113(2): 272–277.
Thiadens HA, De Bock GH, Van Houwelingen JC, et al. Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilator response as assessed by FEV1 in primary care patients presenting with a persistent cough? Thorax. 1999;54(12):1055–1060.
Aggarwal AN, Gupta D, Jindal SK. The relationship between FEV1 and peak expiratory flow in patients with airways obstruction is poor. Chest. 2006;130(5):1454-1461.
Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J. 2005;26(1):153–161.
No authors listed. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152(3):1107–1136.
Dejsomritrutai W, Wongsurakiat P, Chierakul N, Charoenratanakul S, Nana A, Maranetra KN. Comparison between specified percentage and fifth percentile criteria for spirometry interpretation in Thai patients. Respirology. 2002;7(2):123-127.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
Fleiss JL, Levin B, Pail MC. Statistical Methods for Rates and Proportions. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc; 2003.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307–310.
Robinson DR, Chaudhary BA, Speir WA Jr. Expiratory flow limitation in large and small airways. Arch Intern Med. 1984;144(7):1457–1460.
Murata GH, Kapsner CO, Lium DJ, Busby HK. Patient compliance with peak flow monitoring in chronic obstructive pulmonary disease. Am J Med Sci. 1998;315(5):296-301.
de la Iglesia F, Diaz JL, Pita S, et al. Peak expiratory flow rate as predictor of inpatient death in patients with chronic obstructive pulmonary disease. South Med J. 2005;98(3):266-272.
Smith M, Zhou M, Wang L, Peto R, Yang G, Chen Z. Peak flow as a predictor of cause-specific mortality in China: results from a 15-year prospective study of ~170,000 men. Int J Epidemiol. 2013;42(3): 803–815.
© 2015 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.